Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 26, Issue 10, Pages 2034-2043
Publisher
Oxford University Press (OUP)
Online
2015-06-11
DOI
10.1093/annonc/mdv250
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications
- (2015) Ignace B. Vergote et al. CANCER AND METASTASIS REVIEWS
- Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis
- (2015) Roland F. Schwarz et al. PLOS MEDICINE
- Folate Receptor Alpha Expression in Lung Cancer: Diagnostic and Prognostic Significance
- (2015) Daniel J. O'Shannessy et al. Oncotarget
- Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide)
- (2014) R. T. Morris et al. ANNALS OF ONCOLOGY
- Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study
- (2014) M Köbel et al. BRITISH JOURNAL OF CANCER
- Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer
- (2014) Y. Wen et al. CLINICAL CANCER RESEARCH
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Imaging the Folate Receptor on Cancer Cells with 99mTc-Etarfolatide: Properties, Clinical Use, and Future Potential of Folate Receptor Imaging
- (2014) A. H. Maurer et al. JOURNAL OF NUCLEAR MEDICINE
- Juno is the egg Izumo receptor and is essential for mammalian fertilization
- (2014) Enrica Bianchi et al. NATURE
- Development and preclinical evaluation of new 124I-folate conjugates for PET imaging of folate receptor-positive tumors
- (2014) I. AlJammaz et al. NUCLEAR MEDICINE AND BIOLOGY
- An Updated Meta-Analysis of Fatal Adverse Events Caused by Bevacizumab Therapy in Cancer Patients
- (2014) Hongxin Huang et al. PLoS One
- Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease
- (2013) B. J. Monk et al. ANNALS OF ONCOLOGY
- Interobserver Agreement and Assay Reproducibility of Folate Receptor α Expression in Lung Adenocarcinoma: A Prognostic Marker and Potential Therapeutic Target
- (2013) Ryan E. Bremer et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Prognostic significance of FRA expression in epithelial cancers using AQUA®technology
- (2013) Daniel J O’Shannessy et al. Biomarkers in Medicine
- The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity
- (2013) JianMin Lin et al. CANCER BIOLOGY & THERAPY
- Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
- (2013) D Gonzalez de Castro et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy
- (2013) E. Despierre et al. GYNECOLOGIC ONCOLOGY
- Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer
- (2013) Deborah K. Armstrong et al. GYNECOLOGIC ONCOLOGY
- Personalizing Oncology: Perspectives and Prospects
- (2013) John Mendelsohn JOURNAL OF CLINICAL ONCOLOGY
- PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer
- (2013) R. Wendel Naumann et al. JOURNAL OF CLINICAL ONCOLOGY
- Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies
- (2013) Tianhong Li et al. JOURNAL OF CLINICAL ONCOLOGY
- The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
- (2013) Emma L. Barber et al. Journal of Gynecologic Oncology
- Statistical and Practical Considerations for Clinical Evaluation of Predictive Biomarkers
- (2013) M.-Y. C. Polley et al. JNCI-Journal of the National Cancer Institute
- Farletuzumab in lung cancer
- (2013) Anish Thomas et al. LUNG CANCER
- Momentum grows to make 'personalized' medicine more 'precise'
- (2013) Alla Katsnelson NATURE MEDICINE
- Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4
- (2013) Daniel J O’Shannessy et al. Journal of Ovarian Research
- Systemic cancer therapy: achievements and challenges that lie ahead
- (2013) Michael O. Palumbo et al. Frontiers in Pharmacology
- Cellular Heterogeneity and Molecular Evolution in Cancer
- (2012) Vanessa Almendro et al. Annual Review of Pathology-Mechanisms of Disease
- Engineering Folate–Drug Conjugates to Target Cancer: From Chemistry to Clinic
- (2012) Iontcho R. Vlahov et al. BIOCONJUGATE CHEMISTRY
- A novel splice variant of folate receptor 4 predominantly expressed in regulatory T cells
- (2012) Yi Tian et al. BMC IMMUNOLOGY
- Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro
- (2012) B. A. Kamen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance
- (2012) Nitzan Gonen et al. DRUG RESISTANCE UPDATES
- EC145: a novel targeted agent for adenocarcinoma of the lung
- (2012) Pamela Pribble et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors
- (2012) Patricia M. LoRusso et al. JOURNAL OF CLINICAL ONCOLOGY
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Trial of EC145 in Advanced, Folate-Receptor Positive Adenocarcinoma of the Lung
- (2012) Martin J. Edelman et al. Journal of Thoracic Oncology
- Overcoming implementation challenges of personalized cancer therapy
- (2012) Funda Meric-Bernstam et al. Nature Reviews Clinical Oncology
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Optimizing Molecular-Targeted Therapies in Ovarian Cancer: The Renewed Surge of Interest in Ovarian Cancer Biomarkers and Cell Signaling Pathways
- (2012) Donavon Hiss Journal of Oncology
- Mechanisms of Membrane Transport of Folates into Cells and Across Epithelia
- (2011) Rongbao Zhao et al. Annual Review of Nutrition
- Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity
- (2011) S. M. Rudman et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Prospective Molecular Marker Analyses ofEGFRandKRASFrom a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer
- (2011) Wolfram Brugger et al. JOURNAL OF CLINICAL ONCOLOGY
- Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine
- (2011) Q. Tian et al. JOURNAL OF INTERNAL MEDICINE
- Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response
- (2011) Yu-Li Chen et al. Molecular Oncology
- Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results
- (2011) Gooitzen M van Dam et al. NATURE MEDICINE
- Tumor control versus adverse events with targeted anticancer therapies
- (2011) Dorothy M. K. Keefe et al. Nature Reviews Clinical Oncology
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer
- (2011) Lucia M. A. Crane et al. CELLULAR ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Functional Folate Receptor Alpha Is Elevated in the Blood of Ovarian Cancer Patients
- (2009) Eati Basal et al. PLoS One
- Expression Status of Folate Receptor α Is Significantly Correlated with Prognosis in Non-Small-Cell Lung Cancers
- (2008) Shotaro Iwakiri et al. ANNALS OF SURGICAL ONCOLOGY
- Tumor detection using folate receptor-targeted imaging agents
- (2008) Emanuela I. Sega et al. CANCER AND METASTASIS REVIEWS
- Immunohistochemical expression of folate receptor α in colorectal carcinoma: patterns and biological significance
- (2008) Jinru Shia et al. HUMAN PATHOLOGY
- Exploratory Study of 99mTc-EC20 Imaging for Identifying Patients with Folate Receptor-Positive Solid Tumors
- (2008) R. E. Fisher et al. JOURNAL OF NUCLEAR MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started